Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar;68(3):402-411.
doi: 10.1016/j.jhep.2017.10.010. Epub 2018 Jan 8.

Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe

Hannah Fraser  1 , Natasha K Martin  2 , Henrikki Brummer-Korvenkontio  3 , Patrizia Carrieri  4 , Olav Dalgard  5 , John Dillon  6 , David Goldberg  7 , Sharon Hutchinson  8 , Marie Jauffret-Roustide  9 , Martin Kåberg  10 , Amy A Matser  11 , Mojca Matičič  12 , Havard Midgard  13 , Viktor Mravcik  14 , Anne Øvrehus  15 , Maria Prins  16 , Jens Reimer  17 , Geert Robaeys  18 , Bernd Schulte  19 , Daniela K van Santen  20 , Ruth Zimmermann  21 , Peter Vickerman  22 , Matthew Hickman  22
Affiliations

Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe

Hannah Fraser et al. J Hepatol. 2018 Mar.

Abstract

Background & aims: Prevention of hepatitis C virus (HCV) transmission among people who inject drugs (PWID) is critical for eliminating HCV in Europe. We estimated the impact of current and scaled-up HCV treatment with and without scaling up opioid substitution therapy (OST) and needle and syringe programmes (NSPs) across Europe over the next 10 years.

Methods: We collected data on PWID HCV treatment rates, PWID prevalence, HCV prevalence, OST, and NSP coverage from 11 European settings. We parameterised an HCV transmission model to setting-specific data that project chronic HCV prevalence and incidence among PWID.

Results: At baseline, chronic HCV prevalence varied from <25% (Slovenia/Czech Republic) to >55% (Finland/Sweden), and <2% (Amsterdam/Hamburg/Norway/Denmark/Sweden) to 5% (Slovenia/Czech Republic) of chronically infected PWID were treated annually. The current treatment rates using new direct-acting antivirals (DAAs) may achieve observable reductions in chronic prevalence (38-63%) in 10 years in Czech Republic, Slovenia, and Amsterdam. Doubling the HCV treatment rates will reduce prevalence in other sites (12-24%; Belgium/Denmark/Hamburg/Norway/Scotland), but is unlikely to reduce prevalence in Sweden and Finland. Scaling-up OST and NSP to 80% coverage with current treatment rates using DAAs could achieve observable reductions in HCV prevalence (18-79%) in all sites. Using DAAs, Slovenia and Amsterdam are projected to reduce incidence to 2 per 100 person years or less in 10 years. Moderate to substantial increases in the current treatment rates are required to achieve the same impact elsewhere, from 1.4 to 3 times (Czech Republic and France), 5-17 times (France, Scotland, Hamburg, Norway, Denmark, Belgium, and Sweden), to 200 times (Finland). Scaling-up OST and NSP coverage to 80% in all sites reduces treatment scale-up needed by 20-80%.

Conclusions: The scale-up of HCV treatment and other interventions is needed in most settings to minimise HCV transmission among PWID in Europe.

Lay summary: Measuring the amount of HCV in the population of PWID is uncertain. To reduce HCV infection to minimal levels in Europe will require scale-up of both HCV treatment and other interventions that reduce injecting risk (especially OST and provision of sterile injecting equipment).

Keywords: Direct-acting antivirals; Hepatitis C; Opioid substitution therapy; PWID.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Schematics of HCV transmission (1a) and OST and NSP interventions (1b) in the model
a: Infection component of the model b: OST and NSP intervention component of the model
Figure 2
Figure 2. Percentage of estimated PWID with chronic HCV infections treated annually at baseline (2015/16) for each site
Bars indicate the median and interquartile range and whiskers show the 95% credibility intervals.
Figure 3
Figure 3. Baseline and projected 10 year chronic HCV prevalence among PWID in multiple sites in Europe for various treatment intervention scenarios
Baseline chronic prevalence (blue boxes) and projected 10 year chronic prevalence if either current treatment rates continue with new DAAs (green boxes), treatment rates are doubled with new DAAs (yellow boxes), or increased to 50 per 1000 PWID annually with new DAAs (pink boxes). Bars indicate the median and interquartile range and whiskers show the 95% credibility intervals.
Figure 4
Figure 4. Baseline and projected 10 year chronic HCV prevalence among PWID in multiple sites in Europe for various treatment intervention scenarios with OST and NSP scaled-up to 80% coverage
Baseline chronic prevalence (blue boxes) and projected 10-year chronic prevalence if either current treatment rates continue with new DAAs (green boxes), treatment rates are doubled with new DAAs (yellow boxes), or increased to 50 per 1000 PWID annually with new DAAs (pink boxes) with OST and NSP scaled-up to 80% coverage. Bars indicate the median and interquartile range and whiskers show the 95% credibility intervals.
Figure 5
Figure 5. Current and projected number of treatments per 1000 PWID to reduce incidence to 2 per 100 pyrs by 2026
Current number of treatments per 1000 PWID at baseline (2015/16, blue) and required scale-up in number of treatments per 1000 PWID initially needed per year (2016/17) if current OST and NSP coverage is maintained (green, median and 95% credibility interval shown in figure) or if OST and NSP are scaled to 80% coverage (yellow) to reduce incidence to 2 per 100 pyrs (2%) by 2026. Based on data from the sites we have: 1Treatment initially given only to those on OST. 2Treatment initially given to all PWID. 370% treatment to PWIDs on OST, 30% treatment to PWIDs not on OST.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Williams R, et al. Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet. 2014;384(9958):1953–97. - PubMed
    1. Nelson PK, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet. 2011;378(9791):571–583. - PMC - PubMed
    1. Ly KN, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Annals of internal medicine. 2012;156(4):271–278. - PubMed
    1. Cowie B, Allard N, MacLachlan J. O86 EUROPEAN RESPONSES IN FOCUS: COMPARING VIRAL HEPATITIS AND HIV RELATED DEATHS IN EUROPE 1990–2010 IN THE GLOBAL BURDEN OF DISEASE STUDY 2010. Journal of Hepatology. 2014;1(60):S35–S36.
    1. ECDC and EMCDDA. Prevention and control of infectious diseases among people who inject drugs. Stockholm: ECDC; 2011. pp. 4–5.

Publication types

MeSH terms

Substances

LinkOut - more resources